Craft

Eli Lilly

Stock Price

$544.5

2023-09-28

Market Capitalization

$409.3 B

2023-05-03

Revenue

$28.5 B

FY, 2022

Eli Lilly Summary

Company Summary

Overview
Eli Lilly and Company is a company that discovers, develops, manufactures, and markets pharmaceutical products. It offers diabetes and endocrinology, immunology, neuroscience, oncology, and other products. Its products are distributed through wholesalers that serve pharmacies, physicians, and other health care professionals and hospitals.
Type
Public
Status
Active
Founded
1876
HQ
Indianapolis, IN, US | view all locations
Website
https://www.lilly.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • David A. Ricks

    David A. Ricks, Chairman and Chief Executive Officer

  • Anat Ashkenazi

    Anat Ashkenazi, Senior Vice President and Chief Financial Officer

  • Stephen F. Fry

    Stephen F. Fry, Senior Vice President, Human Resources and Diversity

  • Johna L. Norton

    Johna L. Norton, Senior Vice President, Global Quality

    Operating MetricsView all

    Facilities Owned (US), sq. ft.

    8.1M
    1.2%

    FY, 2021

    Facilities Owned, sq. ft.

    12.8M
    1.6%

    FY, 2021

    Phase I Trials Products

    27

    FY, 2019

    LocationsView all

    49 locations detected

    • Indianapolis, IN HQ

      United States

      893 Delaware St

    • Branchburg, NJ

      United States

      33 Imclone Dr

    • Cambridge, MA

      United States

      450 Kendall St

    • Indianapolis, IN

      United States

      1223 W Morris St

    • Indianapolis, IN

      United States

      1500 S Harding St

    • New York, NY

      United States

      450 E 29th St 12th floor

    and 43 others

    Eli Lilly Financials

    Summary Financials

    Revenue (Q2, 2023)
    $8.3B
    Gross profit (Q2, 2023)
    $6.5B
    Net income (Q2, 2023)
    $1.8B
    Cash (Q2, 2023)
    $2.7B
    Enterprise value
    $425.4B

    Footer menu